BioSpace News Archive

Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.

Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB).

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2020 and provides a business update.

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced that it will release its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 14, 2020.

STERIS plc announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020.

Amedisys, Inc. announced that Paul B. Kusserow, President and Chief Executive Officer will present at RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Vaccinex, Inc. announced a poster presentation highlighting interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with the anti-PD-L1 checkpoint inhibitor BAVENCIO® in non-small cell lung cancer, at the American Society of Clinical Oncology 2020 Annual Meeting, being held virtually May 29-31, 2020.

IVX Health, a national network of patient-focused care centers providing biologic infusion and injection therapy, is collaborating with hospitals and health systems across the country to ensure a safe, accessible site of care for immunocompromised patients during the COVID-19 pandemic.

QuVa Pharma, Inc. confirms its ability to provide essential medicines on shortage for the treatment of critically ill COVID-19 patients given the Food and Drug Administration’s (FDA) announcement of the “Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency”,